BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12822409)

  • 1. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
    Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
    Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
    IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
    Yamaguchi M; Konishi I
    Rinsho Ketsueki; 2003 Apr; 44(4):254-6. PubMed ID: 12784659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
    Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A
    J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
    Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
    Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
    Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi QL; Chun K; Kamel-Reid S; Minden MD
    Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
    Parovichnikova EN; Savchenko VG; Verniuk MA; Vinogradova OA; Misiurin AV; Vorob'ev IA; Domracheva EV; Tikhonova LIu; Rukavitsyn OA; Rossiev VA; Kliasova GA; Turkina AG; Liubimova LS; Mendeleeva LP; Isaev VG
    Ter Arkh; 2005; 77(7):11-6. PubMed ID: 16116902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee KH; Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Kim WK; Lee JS; Seo EJ; Jang S; Park CJ; Chi HS
    Leukemia; 2005 Sep; 19(9):1509-16. PubMed ID: 16034462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
    Piccaluga PP; Malagola M; Rondoni M; Amabile M; Paolini S; Soverini S; Gaitani S; Visani G; Baccarani M; Martinelli G
    Eur J Haematol; 2004 Apr; 72(4):302-3. PubMed ID: 15089772
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia].
    Zhang YF; Chen ZM; Lou JY; Ni WM; Wang YG; Meng HT; Tong HY; Qian WB; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):814-8. PubMed ID: 22339953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.